Royalty Pharma (NASDAQ:RPRX) Announces Earnings Results, Misses Estimates By $0.86 EPS

Posted by Stanley Muller on Nov 4th, 2026

Royalty Pharma (NASDAQ:RPRX – Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.32 EPS for the quarter, missing the consensus estimate of $1.18 by ($0.86), FiscalAI reports. Royalty Pharma had a net margin of 32.14% and a return on equity of 30.01%. The business had revenue of $690.10 million during the quarter, compared to analysts’ expectations of $884.84 million.

Here are the key takeaways from Royalty Pharma’s conference call:

Royalty receipts grew 9% in the quarter and 12% year to date, led by products including TREMFYA, Voranigo, Evrysdi and IMDELLTRA; growth absorbed an approximately 5% combined headwind from Promacta and IMBRUVICA.
Royalty Pharma raised its 2026 guidance for the third consecutive quarter, now expecting portfolio receipts of $3.5 billion–$3.55 billion and royalty-receipt growth of 10%–11%.
Management highlighted commercial and pipeline opportunities, including strong IMDELLTRA first-line data, FDA approvals for RASONQUE and WELTRUZA, and five successful pivotal Phase III trials so far in 2026. The company also cited a dozen potential blockbuster launches and more than $1.7 billion in potential future peak royalties from its development-stage pipeline.
Novartis’ pelacarsen failed its Phase III outcomes trial, resulting in a $150 million non-cash impairment. Royalty Pharma said the investment was structured to limit the downside, with SPINRAZA royalties expected to provide $550 million against $500 million funded, a 1.1x return.

Royalty Pharma Stock Up 0.9%

NASDAQ RPRX traded up $0.59 during trading on Wednesday, reaching $66.99. 2,016,930 shares of the company’s stock were exchanged, compared to its average volume of 3,408,460. The stock has a market cap of $38.52 billion, a P/E ratio of 46.21, a price-to-earnings-growth ratio of 1.82 and a beta of 0.37. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.80 and a current ratio of 2.80. The company has a 50 day moving average price of $60.48 and a two-hundred day moving average price of $53.39. Royalty Pharma has a 1 year low of $36.03 and a 1 year high of $67.71.

Royalty Pharma Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a $0.2350 dividend. The ex-dividend date is Friday, November 13th. This represents a $0.94 dividend on an annualized basis and a yield of 1.4%. Royalty Pharma’s dividend payout ratio (DPR) is currently 64.83%.

Insider Activity

In related news, EVP Marshall Urist sold 4,126 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $57.10, for a total transaction of $235,594.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $58.53, for a total value of $5,853,000.00. Following the sale, the executive vice president owned 270,401 shares of the company’s stock, valued at approximately $15,826,570.53. The trade was a 27.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 208,252 shares of company stock valued at $12,324,407. Insiders own 18.84% of the company’s stock.

Wall Street Analyst Weigh In

RPRX has been the topic of a number of recent research reports. Weiss Ratings raised Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, September 14th. TD Cowen lifted their target price on Royalty Pharma from $65.00 to $68.00 and gave the company a “buy” rating in a report on Tuesday, September 8th. Bank of America reissued a “buy” rating on shares of Royalty Pharma in a research note on Wednesday, August 5th. JPMorgan Chase & Co. upped their price target on Royalty Pharma from $58.00 to $62.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Finally, Wall Street Zen cut Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 26th. Eight analysts have rated the stock with a Buy rating. According to MarketBeat.com, Royalty Pharma has a consensus rating of “Buy” and an average target price of $61.57.

Check Out Our Latest Analysis on Royalty Pharma

About Royalty Pharma

(Get Free Report)

Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical royalty investment company that provides funding to life sciences companies, academic institutions, and other organizations in exchange for rights to future payments tied to approved or development-stage medicines. Its business model gives innovators access to capital while allowing Royalty Pharma to participate in the long-term commercial success of pharmaceutical products.

The company acquires and manages royalty interests across a broad range of therapeutic areas, including immunology, oncology, neuroscience, rare diseases, and infectious diseases.